Literature DB >> 10549716

Pharmacokinetics of low molecular weight heparins in animal models.

J Fareed1, K Fu, L H Yang, D A Hoppensteadt.   

Abstract

Low molecular weight heparins (LMWHs) are a diverse group of depolymerized heparin preparations with molecular weights ranging from 1800 to 12,000 Da. Due to manufacturing differences, there are marked structural variations between LMWHs that exhibit distinct pharmacologic and biochemical profiles. Pharmacokinetic studies generally use indirect pharmacodynamic measures, particularly anti-Xa activity. Animal models have shown considerable variation between preparations in anti-Xa activity and other pharmacodynamic measures, including bioavailability and release of tissue factor pathway inhibitor (TFPI). Each LMWH has a specific, assay-dependent pharmacokinetic profile, reinforcing the concept that each LMWH is a distinct, noninterchangeable, pharmaceutical product.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10549716

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

1.  Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins.

Authors:  G J Merli; G J Vanscoy; T L Rihn; J B Groce; W McCormick
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

2.  Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.

Authors:  Geno J Merli; James B Groce
Journal:  P T       Date:  2010-02

3.  Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.

Authors:  Tianzhi Yang; Alamdar Hussain; Jennifer Paulson; Thomas J Abbruscato; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

4.  Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.

Authors:  Klas Norrby; Arvid Nordenhem
Journal:  APMIS       Date:  2010-10-12       Impact factor: 3.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.